Inflammatory Treatment Product Applications

2 applications found

Microbiome Therapeutics for Clinical Trials

Finch’s lead candidate, CP101, is in late-stage clinical development for the prevention of recurrent C. difficile infection (CDI), and has received Breakthrough Therapy and Fast Track designations from the U.S. Food and Drug Administration. In June 2020, Finch announced that CP101 met its primary efficacy endpoint in PRISM3, the first of two pivotal trials to support the development of CP101 for the prevention of recurrent CDI. PRISM4, a Phase 3 trial, is designed to serve as the second pivotal trial of ...

ByFinch Therapeutics Group, Inc. based in Somerville, MASSACHUSETTS (USA)

LLLT (Low Level Laser Therapy/ Photobiomodulation)

Low-level laser therapy (LLLT) is defined as laser treatment in which the energy output is low enough to produce nonthermal and biostimulatory effects. The mechanisms of the effect of LLLT causing laser analgesia are due to the stabilization of depolarising potential of nerve fibers or effects on the cellular and biochemical processes of the inflammatory responses. It is a new treatment modality and has the advantages of being painless with no side effects. ...

ByPIOON based in Wuhan, CHINA

Need help finding the right suppliers?Try XPRT Sourcing. Let the XPRTs do the work for you